Physician profile
Eric D Schroeder
NPI 1861707515
$10,483.37
in general payments reported to CMS, 2019-2025
22 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 79% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,457 · 2020: $496 · 2021: $766 · 2022: $2,907 · 2023: $1,049 · 2024: $721 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Consulting Fee: $1,425 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.79 |
| Consulting Fee | $1,425.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,577.45 | 2019-2025 | Da Vinci Surgical System |
| Eisai INC. | $2,212.58 | 2020-2022 | |
| Abbvie INC. | $2,107.70 | 2019-2025 | |
| Conmed Corporation | $922.48 | 2019-2025 | Airseal |
| Ethicon US, LLC | $366.39 | 2019-2024 | Ethicon, Vistaseal, Enseal |
| Hologic Sales and Service, LLC | $363.18 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $285.26 | 2020-2024 | Keytruda, Lynparza |
| Seagen INC. | $265.08 | 2023 | Tivdak |
| Abbott Laboratories | $241.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $231.97 | 2019 | |
| Medtronic, INC. | $184.00 | 2021 | |
| Astellas Pharma US INC | $132.41 | 2023 | Veozah |
| On Target Laboratories, INC | $120.93 | 2025 | Cytalux |
| Kerecis Limited | $118.42 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Glaxosmithkline, LLC. | $101.58 | 2021-2023 | Zejula, Jemperli |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $100.00 | 2019 | |
| Zoll Circulation INC | $36.63 | 2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Regeneron Healthcare Solutions, INC. | $27.21 | 2025 | Evkeeza |
| Myriad Genetic Laboratories, INC. | $26.84 | 2023 | Myrisk |
| Momentis Surgical INC. | $24.00 | 2022 | |
| Sumitomo Pharma America, INC. | $23.62 | 2023 | Myfembree |
| Angiodynamics, INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.